AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Hot Topics in Atopic Dermatitis 2024

Description

The presentation discussed current hot topics in the understanding and treatment of atopic dermatitis (AD), emphasizing the genetic and inflammatory underpinnings of the disease. The speaker highlighted conflicts of interest but focused on topics such as the atopic march, the role of type 2 inflammation, and the importance of estrangements between skin barrier dysfunction and associated comorbidities like asthma and eosinophilic esophagitis. The speaker discussed genetic predispositions leading to type 2 inflammation and how aggressive early treatment might alter disease trajectory to decrease comorbidities. New findings indicated that topical steroids could effectively reduce Staphylococcus aureus colonization as a byproduct of managing eczema. The speaker stated that clinicians should consider the patient’s mental health, particularly how early and effective treatment of AD can alleviate stress and anxiety related to skin conditions. The importance of utilizing controlled studies over anecdotal evidence was also stressed, as many popular interventions lack efficacy. The discussion concluded by encouraging continuous efforts to improve treatment strategies, emphasizing the need for thorough understanding of genetic factors and the implications of early intervention in managing disease progression and associated health issues.

View more

Conclusions

  • The concept of the 'atopic march' linking eczema to other allergic diseases is unproven according to the 2023 AAD guidelines.
  • Type 2 inflammation is the primary driver of atopic dermatitis and its associated conditions.
  • Genetic predispositions significantly influence the severity and type of atopic dermatitis patients experience.
  • Early and aggressive treatment of atopic dermatitis can potentially alter its disease course and reduce the incidence of comorbidities.
  • There is a strong correlation between atopic dermatitis and increased risks of asthma and eosinophilic esophagitis.
  • Topical steroids can significantly reduce the presence of Staphylococcus aureus in patients with eczema without the use of antibiotics.
  • Comorbidities associated with atopic dermatitis include cardiovascular disease, inflammatory bowel disease, and mental health issues, necessitating careful clinical management.
  • Recent studies suggest that proactive treatment approaches in young patients may reduce the likelihood of developing food allergies.
  • Despite the potential benefits of microbiome therapies, controlled trials have shown them to be ineffective for atopic dermatitis management.
  • The effects of treatments for atopic dermatitis can vary, and some methods (e.g., blue light therapy) show limited effectiveness compared to initial clinical expectations.
  • Bin, L., & Leung, D. Y. M. (2016). Genetic and epigenetic studies of atopic dermatitis. Allergy, Asthma, and Clinical Immunology.
  • Yang, et al. J Allergy Clin Immunol 2023;151:1296-306.
  • Baris S, J Allergy Clin Immunol 2023;152:182-94.e7.
  • Sharma M, et al. Human germline heterozygous gain-of-function STAT6 variants cause severe allergic disease. J Exp Med. 2023 May.
  • Klunk, et al. Nature, 2022.
  • J. Wan, et al. J Allergy Clin Immunol Pract 2023.
  • G. F. Chen and J. M. Cohen, Int J Dermatol 2023 Vol. 62 Issue 10.
  • B. Smith, et al. J Am Acad Dermatol 2023 Vol. 89 Issue 3 Pages 610-613.
  • M. Z. Joel, W. Damsky and J. M. Cohen Clin Exp Dermatol 2023.
  • Bieber T. Disease modification in inflammatory skin disorders: opportunities and challenges. Nat Rev Drug Discov. 2023 Aug;22(8):662-680. doi: 10.1038/s41573-023-00735-0. Epub 2023 Jul 13.
  • Roduit C, et al. The Journal of Allergy and Clinical Immunology. 2012;130(1):130-6.e5. doi: 10.1016/j.jaci.2012.02.043.
  • Irvine AD, Mina-Osorio P. Disease trajectories in childhood atopic dermatitis: an update and practitioner's guide. The British journal of dermatology. 2019;181(5):895-906. Epub 2019/02/14. doi: 10.1111/bjd.17766. PubMed PMID: 30758843; PMCID: PMC6899789.
  • Yamamoto-Hanada K, et al. Enhanced early skin treatment for atopic dermatitis in infants reduces food allergy. J Allergy Clin Immunol. 2023 Mar 22:S0091-6749(23)00331-7. Epub ahead of print.
  • Blauvelt A, et al. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). Am J Clin Dermatol. 2022 May;23(3):365-383.
  • Rose C. Velasco, et al. Treatment of Topical Corticosteroid Withdrawal: A Case Series. Dermatitis, 2023.
  • Myles IA, et al. First-in-human topical microbiome transplantation with Roseomonas mucosa for atopic dermatitis. JCI Insight. 2018 May 3;3(9).
  • Matthew J Ridd, et al. The Best Emollient for Eczema (BEE) trial: a randomised trial comparing the effectiveness of four types of commonly prescribed emollients for children with eczema.
  • Manon M. Sloot, et al. Effectiveness of antibacterial therapeutic clothing vs. nonantibacterial therapeutic clothing in patients with moderate-to-severe atopic dermatitis: a randomized controlled observer-blind pragmatic trial (ABC trial).
  • J Eur Acad Dermatol Venereol 2023 Vol. 37 Issue 10 Pages e1211-e1214.